Amit Surve1, James Potts1, Daniel Cottam2, Mitchell Roslin3, Walter Medlin1, Miro Uchal4, Christina Richards1, Legrand Belnap1. 1. Bariatric Medicine Institute, 1046 East 100 South, Salt Lake City, UT, USA. 2. Bariatric Medicine Institute, 1046 East 100 South, Salt Lake City, UT, USA. drdanielcottam@yahoo.com. 3. Northwell Health-Lenox Hill Hospital, New York City, NY, USA. 4. North Florida Surgeons, Jacksonville, FL, USA.
Abstract
BACKGROUND: Thromboprophylaxis in bariatric surgery is widely debated; however, few large articles evaluate treatment plans and their efficacy. Herein, we make the first large-scale report of the safety and efficacy of apixaban (Eliquis) for thrombus prevention following bariatric surgery. PURPOSE: To evaluate the safety and efficacy of apixaban following bariatric surgery. SETTING: Three private institutes, USA. MATERIALS AND METHODS: Data from 5017 consecutive bariatric patients that were placed on postoperative apixaban for thromboprophylaxis were used for retrospective analysis. The dose prescribed to patients was 2.5 mg PO BID for a total of 30 days starting on day 3 postoperatively. RESULTS: In total, of the 5017 patients, 59.7%, 31.2%, 4.4%, 2.5%, 1.8%, and 0.1% of the patients had undergone sleeve gastrectomy (SG), single-anastomosis duodeno-ileal bypass with SG (SADI-S), Roux-en-Y gastric bypass (RYGB), conversion from SG to SADI, small bowel reconstruction, and RYGB reversal, respectively. The 30-day follow-up rate was 95.3%. In total, 1.7% of patients experienced apixaban-related side effects. The most common side effects were menorrhagia and rash. Two (0.03%) side effects developed into Clavien-Dindo grade II complications. Overall, 10 (0.1%) patients experienced thromboembolic complications (five (0.09%) PVTs and five (0.09%) PEs). In each case, the protocol was not followed for extenuating circumstances. There were no deaths or thromboembolic events in cases where the protocol was able to be fully followed. CONCLUSIONS: In conclusion, 30 days of postoperative apixaban appears to be safe and effective with minimal side effects while preventing thromboembolic events.
BACKGROUND: Thromboprophylaxis in bariatric surgery is widely debated; however, few large articles evaluate treatment plans and their efficacy. Herein, we make the first large-scale report of the safety and efficacy of apixaban (Eliquis) for thrombus prevention following bariatric surgery. PURPOSE: To evaluate the safety and efficacy of apixaban following bariatric surgery. SETTING: Three private institutes, USA. MATERIALS AND METHODS: Data from 5017 consecutive bariatric patients that were placed on postoperative apixaban for thromboprophylaxis were used for retrospective analysis. The dose prescribed to patients was 2.5 mg PO BID for a total of 30 days starting on day 3 postoperatively. RESULTS: In total, of the 5017 patients, 59.7%, 31.2%, 4.4%, 2.5%, 1.8%, and 0.1% of the patients had undergone sleeve gastrectomy (SG), single-anastomosis duodeno-ileal bypass with SG (SADI-S), Roux-en-Y gastric bypass (RYGB), conversion from SG to SADI, small bowel reconstruction, and RYGB reversal, respectively. The 30-day follow-up rate was 95.3%. In total, 1.7% of patients experienced apixaban-related side effects. The most common side effects were menorrhagia and rash. Two (0.03%) side effects developed into Clavien-Dindo grade II complications. Overall, 10 (0.1%) patients experienced thromboembolic complications (five (0.09%) PVTs and five (0.09%) PEs). In each case, the protocol was not followed for extenuating circumstances. There were no deaths or thromboembolic events in cases where the protocol was able to be fully followed. CONCLUSIONS: In conclusion, 30 days of postoperative apixaban appears to be safe and effective with minimal side effects while preventing thromboembolic events.
Authors: David A Froehling; Paul R Daniels; Karen F Mauck; Maria L Collazo-Clavell; Aneel A Ashrani; Michael G Sarr; Tanya M Petterson; John A Heit Journal: Obes Surg Date: 2013-11 Impact factor: 4.129
Authors: Ali Aminian; Amin Andalib; Zhamak Khorgami; Derrick Cetin; Bartolome Burguera; John Bartholomew; Stacy A Brethauer; Philip R Schauer Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: LeGrand Belnap; George M Rodgers; Daniel Cottam; Hinali Zaveri; Cara Drury; Amit Surve Journal: Surg Obes Relat Dis Date: 2016-03-08 Impact factor: 4.734
Authors: Banne Nemeth; Willem M Lijfering; Rob G H H Nelissen; Inger B Schipper; Frits R Rosendaal; Saskia le Cessie; Suzanne C Cannegieter Journal: JAMA Netw Open Date: 2019-05-03
Authors: Hui Jiang; Jia Meng; Ting Guo; Jian Ning Zhao; Yi Cun Wang; Jun Wang; Yang Qiu; Hao Ding Journal: Yonsei Med J Date: 2019-07 Impact factor: 2.759